Initial experiences with the Hemopatch® as a hemostatic agent in zero-ischemia partial nephrectomy.

Area of Science:

• Urology
• Surgical Oncology
• Minimally Invasive Surgery

Background:

• Nephron-sparing surgery (NSS) is the standard for resectable renal tumors.
• Laparoscopic partial nephrectomy (LPN) has advanced with improved techniques and hemostatic agents.
• Zero-ischemia techniques minimize renal damage during LPN.

Purpose of the Study:

• To evaluate the initial experience with Hemopatch®, a novel hemostatic agent, in zero-ischemia LPN.
• To assess the safety and efficacy of Hemopatch® in controlling bleeding during LPN.

Main Methods:

• Seven patients with renal masses underwent zero-ischemia LPN.
• Hemopatch® was applied to the tumor resection site after parenchymal suturing.
• Data collected included tumor characteristics, operative details, blood loss, and complications.

Main Results:

• Hemopatch® provided sufficient hemostasis in all seven patients.
• No uncontrolled bleeding or postoperative complications were observed.
• Median operative time was 139 minutes, median blood loss was 325 cc, and median hospitalization was 6 days.

Conclusions:

• Hemopatch® is a feasible and reliable hemostatic agent for zero-ischemia LPN.
• Further studies are needed to confirm its role in NSS.
• Hemopatch® shows promise as a valuable tool in nephron-sparing surgery.